All AbMole products are for research use only, cannot be used for human consumption.

LY2157299 (Galunisertib) could inhibit TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells. Furthermore, administration of LY2157299 ameliorated anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure in vivo. LY2157299 also shows dose dependent potentiation of VEGF or bFGF induced cell proliferation in HUVEC. LY2157299 blocked the phsophorylation of Smad2 but had no effect on fibroblast growth factor (FGF) or platelet-derived growth factor (PDGF) signaling. In the in vitro VEGF-stimulated cord formation assay, LY2157299 potentiates angiogenesis. LY2157299 induces angiogenesis and enhances VEGF and basic-fibroblast-growth-factor-induced angiogenesis in a Matrigel-plug assay, whereas adding an alpha5-integrin-neutralizing antibody to the Matrigel selectively inhibits this enhanced response.
Composites Part B. 2023 Feb 15;110487.
Construction of tissue-engineered vascular grafts with high patency by mimicking immune stealth and blocking TGF-β mediated endothelial-to-mesenchymal transition
LY2157299 purchased from AbMole
Patent. WO2021047775A1 2021 Mar 18.
Patent. WO2021047775A1
LY2157299 purchased from AbMole
EMBO Mol Med. 2019 Aug;11(8):e9830.
An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma.
LY2157299 purchased from AbMole
Patent. WO2016066665A1 2016 May 06.
Patent. WO2016066665A1
LY2157299 purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | HCC cell |
| Preparation method | HCC cells were incubated in serum-free medium overnight and treated with 5 ng/mL of TGF-β for 1 hour followed by the addition of 1 or 10 μM galunisertib for 5 and 24 hours. Concentrations were selected to be in the range of observed plasma exposure |
| Concentrations | 1 or 10 µM |
| Incubation time | 5 and 24 h |
| Animal Experiment | |
|---|---|
| Animal models | Sprague-Dawley male rats |
| Formulation | 0.9% NaCl water |
| Dosages | 75 mg/kg/day |
| Administration | intragastrically |
| Molecular Weight | 369.42 |
| Formula | C22H19N5O |
| CAS Number | 700874-72-2 |
| Solubility (25°C) | DMSO 80 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related TGF-β Receptor Products |
|---|
| GW788388
GW788388 is a potent selective inhibitor of TGF-beta type I receptor and ALK5 with IC50 values of 0.093 and 0.018 μM. |
| LY364947
LY364947 is a selective small molecule inhibitor of the TGFβ type I receptor kinase with IC50 of 59 nM. |
| LY2109761
LY2109761 is a novel TGF-β receptor type I and type II dual inhibitor, with Ki values of 38 nM and 300 nM, respectively. |
| SB-525334
SB-525334 is a potent activin receptor-like kinase (ALK5)/ type I TGFβ-receptor kinase inhibitor with IC50 of 14.3 nM. |
| SB-505124
Sb-505124 is a selective inhibitor of TGF-βI receptor (ALK4, ALK5, ALK7) with IC50 values of 129 nM and 47 nM for ALK4 and ALK5, respectively. Sb-505124 also inhibits ALK7, but not ALK1, 2, 3 and 6. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
